首页> 外文期刊>British Journal of Medical Practitioners >Eslicarbazepine use in Multiple Sclerosis with refractory Trigeminal Neuralgaia
【24h】

Eslicarbazepine use in Multiple Sclerosis with refractory Trigeminal Neuralgaia

机译:依斯卡西平用于难治性三叉神经痛的多发性硬化症

获取原文
       

摘要

When associated with Multiple Sclerosis (MS), Trigeminal Neuralgia (TN) is often bilateral and more refractory to treatment. Carbamazepine is the first line of treatment for TN, however, common side effects of carbamazepine such as hyponatremia occasionally limit its use.We report the case of a 62 year old female patient with a well controlled MS associated TN using carbamazepine. This drug needed to be discontinued because of recurrent symptomatic hyponatremia. Several agents including topiramate, gabapentine and amitriptyline were tried but none had any beneficial effect on TN. A small dose of eslicarbazepine (400 mg daily) provided excellent control of the TN pain on one hand and did not affect the plasma sodium levels on the other hand.Eslicarbazepine main advantage is providing the same effects of carbamazepine or oxcarbazepine but with an incidence of hyponatremia of less than 1%. It is much safer to use when the risk of hyponatremia is increased. To our knowledge, this is the first case that reports the use of eslicarbazepine in one of the several indications of carbamazepine such as pain and mental health problems. Eslicarbazepine use in epilepsy was reported extensively.We feel that a therapeutic trial of eslicarbazepine is justified when either carbamazepine or oxcarbazepine have to be discontinued because of hyponatremia despite their efficacy.
机译:与多发性硬化症(MS)相关时,三叉神经痛(TN)通常是双侧的,对治疗更难治。卡马西平是TN的第一线治疗方法,但是,卡马西平常见的副作用(如低钠血症)偶尔会限制其使用。我们报道了62岁的女性患者,使用卡马西平可很好地控制MS相关性TN。由于反复出现症状性低钠血症,需要停药。尝试了几种药物,包括托吡酯,加巴喷丁和阿米替林,但均未对TN产生任何有益作用。少量的依斯卡西平(每天400 mg)一方面可以很好地控制TN疼痛,另一方面不影响血浆钠水平。依斯卡西平的主要优点是具有与卡马西平或奥卡西平相同的作用,但发生率高低钠血症小于1%。当发生低钠血症的风险增加时,使用它会更加安全。据我们所知,这是第一个报告使用依斯卡西平治疗卡马西平的几种适应症之一,例如疼痛和心理健康问题的病例。依斯卡西平在癫痫病中的应用已有广泛报道。我们认为,尽管卡马西平或奥卡西平因低钠血症而不得不停药,尽管疗效确切,但仍可进行依斯卡西平的治疗试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号